Drug Search Results
More Filters [+]

NEURON-012703

Alternative Names: neuron-012703, neuron012703, neuron 012703
Latest Update: 2012-02-23
Latest Update Note: Clinical Trial Update

Product Description

Amino acid formulation for the dietary management of symptoms related to periphal neuropathy. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01537705)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Targeted Medical Pharma
Company Location: LOS ANGELES CA 90077
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for NEURON-012703

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Peripheral Nervous System Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Neuron012703

P2

Unknown status

Peripheral Nervous System Diseases

2012-07-01

Recent News Events

Date

Type

Title